Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care...
Read More
Oncology
Biosimilar MW032 Vs Denosumab for Solid Tumor–Related Bone Metastases
1. The change of uNTx/uCr (a marker of bone resorption) was within the equivalence margin in the...
Read More
Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease
1. In patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC), immune...
Read More
Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone)...
Read More
Updated Outcomes of Sacituzumab Govitecan in Resistant Advanced Urothelial Carcinoma
1. The objective response rate was 28% with a complete response of 5.6% and a partial response of...
Read More
Atezolizumab in addition to bevacizumab and platinum-based chemotherapy improves survival in metastatic cervical cancer
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival...
Read More
Worse breast cancer death rates for non-screen detected ductal carcinoma situ
1. Women with non-screen detected ductal carcinoma in situ had worse outcomes for the 25 years...
Read More
Preserving Pulmonary Function’s Clinical Impact Following Lung Resection in Early-Stage NSCLC
The following is a summary of “Clinical significance of preserving pulmonary function after lung...
Read More
Mirtazapine improves caloric intake compared to placebo in patients with advanced non-small cell lung cancer
1. While perceived appetite did not differ between study groups, patients receiving mirtazapine...
Read More
Low dose olanzapine in non-inferior to standard dose in terms of anti-emetic effect in patients receiving emetogenic chemotherapy
1. Low dose Olanzapine (2.5 mg) demonstrated similar anti-emetic effect to standard dose...
Read More
Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2....
Read More
Pembrolizumab and chemotherapy combination improves survival in advanced pleural mesothelioma
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall...
Read More
Pembrolizumab Enhances Progression-Free Survival in HER2-Positive Gastro-Esophageal Cancer
Findings suggest that pembrolizumab, added to trastuzumab and chemotherapy, enhances...
Read More
Prolonged rituximab maintenance therapy does not provide overall survival benefit in low-burden follicular lymphoma
1. In patients with low tumor burden follicular lymphoma (LTBFL): Rituximab maintenance therapy...
Read More
Optimizing Subtyping-Based Therapy in Triple-Negative Breast Cancer
1. The median progression-free survival was improved with the pooled subtyping-based therapy group...
Read More
Mobile application communication may improve palliative care needs met in critically ill patients
1. Families randomized to having access to a mobile application that allowed them to communicate...
Read More
Perioperative Pembrolizumab Boosts Response in Localized Gastric Cancer Treatment
In a study on perioperative pembrolizumab with cisplatin-based or FLOT-based chemotherapy for...
Read More
Computed Tomography coronary calcium scores may predict risk of cardiovascular events in cancer patients
1. Despite lower prevalence of traditional cardiovascular risk factors, cancer patients were...
Read More
Pembrolizumab enhances progression-free survival in patients with HER2-positive gastro-esophageal cancer
1. Progression-free survival was significantly greater among patients in the pembrolizumab group...
Read More
Comparison of two chemotherapy regimens in muscle invasive bladder cancer
1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year...
Read More